Aglaia is founded on the principle that the willingness to take risks on the very early stage ventures of today results in opportunities
Business Model:
Revenue: $10.1M
Employees: 2-10
Address: Professor Bronkhorstlaan 10, building 92
City: Bilthoven
State: other
Zip: 3723
Country: NL
Aglaia is founded on the principle that the willingness to take risks on the very early stage ventures of today results in opportunities that may grow into the winning companies of tomorrow. As such, we are typically the first provider of capital for startup and early stage companies and a driving force behind product development. Since the number of technological discoveries in the biomedical field is growing fast, specialized knowledge regarding the translation of these discoveries into novel products is a prerequisite for success. Aglaia&s;s focus on oncology is considered to be a differentiating asset. We invest in novel tools and technologies as well as components of contemporary drug development. Opportunities may be derived from research centers as well as from corporate spinouts. We select, develop and commercialize promising technologies up to a level where the technology becomes attractive to larger investors or pharmaceutical and biotech companies.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
12/2015 | Inthera Bioscience | Seed Round | 0 |
4/2018 | Mimetas | Series B | 0 |
12/2015 | InteRNA Technologies | Series A | 0 |
1/2017 | Macrophage Pharma | Series A | 0 |
1/2010 | Merus | Series B | 0 |
10/2021 | Sapreme Technologies | Series A | 0 |
1/2017 | Cristal Therapeutics | Venture Round | 0 |
6/2018 | Inthera Bioscience | Series A | 0 |
2/2021 | InteRNA Technologies | Series B | 0 |
5/2017 | Inthera Bioscience | Series A | 0 |
10/2021 | Sapreme Technologies | Series A | 0 |
2/2021 | InteRNA Technologies | Series B | 0 |
6/2018 | Inthera Bioscience | Series A | 0 |
4/2018 | Mimetas | Series B | 0 |
5/2017 | Inthera Bioscience | Series A | 0 |
1/2017 | Cristal Therapeutics | Venture Round | 0 |
1/2017 | Macrophage Pharma | Series A | 0 |
12/2015 | InteRNA Technologies | Series A | 0 |
12/2015 | Inthera Bioscience | Seed Round | 0 |
1/2010 | Merus | Series B | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|